<unk><unk>  is not curable, but it can often be treatable for many years. In<unk>  associated with immunodeficiency or immunosuppression, treating the cause of the immune system dysfunction can slow or stop the progression of<unk> . In 40% or more of patients with AIDS-associated<unk><unk> , the<unk>  lesions will shrink upon first starting highly active antiretroviral therapy (HAART). Therefore, HAART is considered the cornerstone of therapy in AIDS-associated<unk><unk> . However, in a certain percentage of such people,<unk><unk>  may recur after many years on HAART, especially if HIV is not completely suppressed. People with a few local lesions can often be treated with local measures such as radiation therapy or cryosurgery. Weak evidence suggests that antiretroviral therapy in combination with chemotherapy is more effective than either of those two therapies individually. Limited basic and clinical evidence suggest that topical beta-blockers, such as timolol, may induce regression of localized lesions in classic as well as HIV-associated<unk><unk> . In general, surgery is not recommended, as<unk><unk>  can appear in wound edges. In general, more widespread disease, or disease affecting internal organs, is treated with systemic therapy with interferon alpha, liposomal anthracyclines (such as liposomal doxorubicin or daunorubicin), thalidomide, or paclitaxel. Alitretinoin, applied to the lesion, may be used when the lesion is not getting better with standard treatment of HIV/AIDS and chemotherapy or radiation therapy cannot be used.
Kaposi's sarcoma
Melanoma
Mule spinners' cancer
Melanocytic nevus
Ewing's sarcoma
Blue rubber bleb nevus syndrome
Lymphangiosarcoma
Pyogenic granuloma